神马电影717,中文字幕在线观看国产,最全精品自拍视频在线,天天摸天天爽天天澡视频

首頁(yè) /藥靶模型 /激酶靶點(diǎn) /RET /KIF5B(E15)-RET(E12)-Long/BaF3

KIF5B(E15)-RET(E12)-Long/BaF3

CBP73195

詢 價(jià)
留 言
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫(kù)
I. Introduction
Cell Line Name: KIF5B(E15)-RET(E12)-Long/BaF3
Host Cell: BA/F3
Stability: 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Application: Anti-proliferation assay and PD assay
Freeze Medium: 90% FBS+10% DMSO
Complete Culture Medium: RPMI-1640+10%FBS+2ug/ml puromycin
Mycoplasma Status: Negative
 
II. Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.

 
III. Representative Data

1. WB of KIF5B-RET (K15, R12L)/BaF3

2. Anti-proliferation assay

Figure 2. CTG Proliferation Assay of BaF3 KIF5B-Ret (L) Cells (C2).

 

客服

微信

掃一掃,添加二維碼

電話

留言

藥靶模型聯(lián)系方式: 華東銷售經(jīng)理(上海):18240630236 華東銷售經(jīng)理(上海、江蘇、安徽):15715191010 華北銷售經(jīng)理:18628311252 華南銷售經(jīng)理:13823536064 華中&華西銷售經(jīng)理:18071545918 華中&西南銷售經(jīng)理:13871580511 全國(guó)銷售經(jīng)理:13816461235
診斷標(biāo)準(zhǔn)品聯(lián)系方式: 華東銷售經(jīng)理:15000320447 華北銷售經(jīng)理:18628311252 華南銷售經(jīng)理:13823536064 華中&華西銷售經(jīng)理:18071545918 華中&西南銷售經(jīng)理:13871580511 全國(guó)銷售經(jīng)理:13816461235

掃二維碼

立即提交
江安县| 龙岩市| 宝坻区| 西贡区| 鄂州市| 海晏县| 营口市| 奉新县| 阿尔山市| 温州市| 景宁| 合作市| 崇明县| 虞城县| 大名县| 嘉定区| 会东县| 西吉县| 恩平市| 奈曼旗| 台安县| 宜兴市| 张家界市| 芮城县| 济阳县| 邯郸市| 普宁市| 武宣县| 达尔| 喀喇| 浠水县| 宜良县| 隆德县| 万安县| 景泰县| 富源县| 泾川县| 虹口区| 大英县| 朝阳县| 漳浦县|